Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the year ended December 31, 2013.
“2013 was a productive and eventful year for Retrophin,” said Martin Shkreli, Founder and Chief Executive Officer of Retrophin. “We added significant assets to our pipeline of drugs for debilitating and life-threatening diseases for which patients have limited or no available treatment options.
Help employers find you! Check out all the jobs and post your resume.
